Company Overview
| Stock Name | 綠葉製藥集團有限公司 |
|---|---|
| Stock Code | 02186 |
| Company Full Name | 綠葉製藥集團有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事開發、生產、推廣及銷售藥品，專注於腫瘤科、中樞神經系統、心血管系統及消化與代的治療領域。 |
| Listing Date | 2014-07-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國山東省煙臺市高新區創業路15號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.luye.cn |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 5.92 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 11.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 591,786,880 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 6.7 |
|---|---|
| First Day Open | HK$ 6.8 |
| First Day Change | 13.18% |
| First Day Volume | 258195000.0 |
| First Day Turnover | 1735020000.0 |
Use of Proceeds
| Use of Proceeds | 1、所得款項凈額約20%或約718百萬港元用于通過引入授權及其他安排（包括選擇性獲取經批準藥品的生產權或銷售及市場推廣權），旨在補充我們的現有藥品組合； 2、所得款項凈額約20%或約718百萬港元用于研發（包括現有及未來中國及海外藥物開發項目）及涉及研發技術或進一步加強我們的研發能力及在研產品計劃的投資； 3、所得款項凈額約20%或約718百萬港元用于選擇性收購國內外醫藥公司； 4、所得款項凈額約20%或約718百萬港元用于撥充資本開支項目，通過構建新生產線以及升級及進一步推動現有生產設施自動化以增加我們的產能，以應對預期增加的我們目前產品及在研產品的需求； 5、所得款項凈額約5%或約180百萬港元用于通過雇傭額外的市場推廣及銷售人員（包括專注于中樞神經系統產品的專責銷售人員）擴展我們的銷售及市場推廣網絡，設立額外的地區辦事處以增強我們現有產品的市場滲透，實現我們成功開發的在研產品的商業化及提高市場推廣及促銷活動（包括我們通過內部銷售團隊進行的學術推廣）的水平； 6、所得款項凈額約5%或約180百萬港元將用于部份償還美元抵押貸款下的借款； 7、所得款項凈額約10%或約360百萬港元將用作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
UBS Securities Hong Kong Limited CE BIN466
花旗环球金融亚洲有限公司 CE AAA137
CITIC Securities Corporate Finance (HK) Limited CE ABF671
Overall Coordinators (3)
UBS Securities Hong Kong Limited CE BIN466
花旗环球金融亚洲有限公司 CE AAA137
中信里昂证券有限公司 CE AAB893
Joint Bookrunners (3)
UBS Securities Hong Kong Limited CE BIN466
花旗环球金融亚洲有限公司 CE AAA137
中信里昂证券有限公司 CE AAB893
Joint Lead Managers (3)
UBS Securities Hong Kong Limited CE BIN466
花旗环球金融亚洲有限公司 CE AAA137
中信里昂证券有限公司 CE AAB893
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Dragon Billion China Master Fund | 406,094,240 HKD | — | 2.06% | — | 6 months | 2015-01-09 |
| 2 | OrbiMed Funds | 406,094,240 HKD | — | 2.07% | — | 6 months | 2015-01-09 |
| 3 | TAL China Focus Master Fund | 243,658,320 HKD | — | 1.24% | — | 6 months | 2015-01-09 |
| 4 | 惠理基金管理香港有限公司 | 812,191,440 HKD | — | 4.13% | — | 6 months | 2015-01-09 |
| 5 | 麦格理基金管理(香港)有限公司 | 203,047,120 HKD | — | 1.03% | — | 6 months | 2015-01-09 |
| 6 | 五矿资本(香港)有限公司 | 203,047,120 HKD | — | 1.03% | — | 6 months | 2015-01-09 |
Directors & Management
| Chairman | 劉殿波 |
|---|---|
| Company Secretary | 李美儀 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 劉殿波及關連人士(35.42%);Hillhouse NEV Holdings Limited(15.56%) |
|---|
